Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.
Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.
Lire l’article complet sur le site source
Global News (EN)